<SEC-DOCUMENT>0001004878-17-000189.txt : 20170811
<SEC-HEADER>0001004878-17-000189.hdr.sgml : 20170811
<ACCEPTANCE-DATETIME>20170811162942
ACCESSION NUMBER:		0001004878-17-000189
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170811
DATE AS OF CHANGE:		20170811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205444
		FILM NUMBER:		171025492

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prosupp424b3aug-17.txt
<DESCRIPTION>PRO SUPP RE SERIES DD WARRANT EXTENSION
<TEXT>
PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement                            Registration No. 333-205444
 dated December 8, 2016)


                               CEL-SCI CORPORATION
                               Series DD Warrants



On August 9, 2017,  the Company  extended the  expiration  date of its Series DD
Warrants by one month from August 10, 2017 to September 10, 2017.  The Series DD
warrants  were issued as part of a financing on December 8, 2016. As a result of
the reverse stock split  approved by the Company's  shareholders  and adopted by
the Company's  directors,  the holders of the Series DD warrants are entitled to
purchase  1,360,960 shares of the Company's common stock at an exercise price of
$4.50 per share.



..































                   Prospectus Supplement dated August 9, 2017
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
